Others are investigating the potential for dual-acting compounds that target both STS and ERα (398) or STS and aromatase (399), and second-generation STS inhibitors have been shown to be effective against E2S-stimulated breast cancer in vivo (393). Here, CYP19A1 is linked to breast cancer.